ACY3抗体

+ +

•  

   

     Western blot analysis using CD3E mouse mAb against Jurkat (1) cell lysate.    

  
  

•  

   

     Flow cytometric analysis of Jurkat cells using CD3E mouse mAb (green) and negative control (purple).    

  
  

The ACY3 antibody targets the aminoacylase 3 (ACY3) enzyme, a member of the M20 metalloprotease family involved in hydrolyzing N-acylated amino acids. ACY3 is primarily expressed in the brain, kidneys, and testes, with proposed roles in neurotransmitter regulation, detoxification, and cellular metabolism. Its function remains understudied compared to other aminoacylases, but emerging research links ACY3 to neurological disorders, cancer progression, and metabolic syndromes.

ACY3 antibodies are essential tools for detecting protein expression, localization, and quantification in research. They are commonly used in techniques like Western blotting, immunohistochemistry, and immunofluorescence. Polyclonal and monoclonal variants exist, with specificity validated through knockout controls or siRNA knockdowns. Some studies highlight ACY3's potential as a biomarker; for example, its downregulation in glioblastoma or altered expression in prostate cancer.

Commercial ACY3 antibodies are typically raised against human or murine epitopes, with cross-reactivity varying by species. Researchers must verify antibody performance in specific experimental systems, as non-specific binding has been reported. Recent investigations also explore ACY3's interaction with cellular pathways like mTOR signaling, suggesting broader regulatory impacts. Despite incomplete mechanistic understanding, ACY3 antibodies remain critical for unraveling its biological significance and therapeutic potential.